Comments
Dr Reddy's Laboratories Ltd has launched its fourth biologic drug, Peg-grafeel for cancer patients, in the domestic market.
Peg-grafeel, sold in pre-filled syringes, was approved in India to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy.
Neutropenia is the condition in which a patient has a lower than normal white blood cell count and is a common side effect of many chemotherapy regimens. The drug is priced at Rs 8,865. This is approximately 25 per cent of the originator brand in India and 95 per cent lower than the US price for pegfilgrastim, it claimed.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.